Published in Clin Infect Dis on January 29, 2003
Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab (2008) 3.64
Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis (2010) 2.20
Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS (2007) 1.95
Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother (2004) 1.90
Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr (2010) 1.87
Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab (2006) 1.72
Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int (2005) 1.40
Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci U S A (2010) 1.38
Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045. AIDS (2010) 1.35
Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr (2008) 1.26
Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. Antivir Ther (2011) 1.23
HIV: inflammation and bone. Curr HIV/AIDS Rep (2012) 1.23
Fractures after antiretroviral initiation. AIDS (2012) 1.21
The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis. Scientifica (Cairo) (2013) 1.20
Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study. AIDS (2010) 1.19
Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection. Hepatology (2012) 1.16
Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. J Clin Endocrinol Metab (2009) 1.16
Higher rates of bone loss in postmenopausal HIV-infected women: a longitudinal study. J Clin Endocrinol Metab (2011) 1.16
Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One (2012) 1.14
Metabolic complications and treatment of perinatally HIV-infected children and adolescents. J Int AIDS Soc (2013) 1.09
Prospective study of bone mineral density changes in aging men with or at risk for HIV infection. AIDS (2010) 1.06
HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture. Curr Opin Endocrinol Diabetes Obes (2010) 1.05
Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection. PLoS Pathog (2014) 1.03
Prevalence and risk factors of low bone mineral density among perinatally HIV-infected Thai adolescents receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2012) 0.99
Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142. HIV Clin Trials (2013) 0.99
HIV and bone metabolism. Discov Med (2011) 0.95
A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS (2009) 0.94
Effect of supplementation with cholecalciferol and calcium on 2-y bone mass accrual in HIV-infected children and adolescents: a randomized clinical trial. Am J Clin Nutr (2012) 0.94
Increased Fracture Incidence in Middle-Aged HIV-Infected and HIV-Uninfected Women: Updated Results From the Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2015) 0.94
Association of regional body composition with bone mineral density in HIV-infected and HIV-uninfected women: women's interagency HIV study. J Acquir Immune Defic Syndr (2012) 0.90
Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study. AIDS (2014) 0.87
Current progress in the development of a prophylactic vaccine for HIV-1. Drug Des Devel Ther (2010) 0.85
Prospective evaluation of bone mineral density among middle-aged HIV-infected and uninfected women: Association between methadone use and bone loss. Maturitas (2011) 0.85
Low bone-mineral density in patients with HIV: pathogenesis and clinical significance. Curr Opin Endocrinol Diabetes (2006) 0.85
Aging and HIV infection. J Urban Health (2006) 0.85
Update on imaging of non-infectious musculoskeletal complications of HIV infection. Skeletal Radiol (2012) 0.84
Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation. BMC Musculoskelet Disord (2008) 0.84
Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART). Eur J Med Res (2009) 0.84
Dairy calcium intake and lifestyle risk factors for bone loss in hiv-infected and uninfected Mediterranean subjects. BMC Infect Dis (2012) 0.84
Metabolic bone disease in human immunodeficiency virus-infected children. J Clin Endocrinol Metab (2004) 0.84
HIV and Bone Disease: A Perspective of the Role of microRNAs in Bone Biology upon HIV Infection. J Osteoporos (2013) 0.83
Recognizing and treating secondary osteoporosis. Nat Rev Rheumatol (2012) 0.82
An Increased Risk of Osteoporosis during Acquired Immunodeficiency Syndrome. Int J Med Sci (2004) 0.82
Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIV-infected patients. Osteoporos Int (2013) 0.82
Fracture risk by HIV infection status in perinatally HIV-exposed children. AIDS Res Hum Retroviruses (2011) 0.82
Impact of age on markers of HIV-1 disease. Future Virol (2013) 0.82
Efavirenz is associated with higher bone mass in South African children with HIV. AIDS (2016) 0.82
Bone disease in HIV infection. Clin Cases Miner Bone Metab (2011) 0.81
Trabecular and cortical microarchitecture in postmenopausal HIV-infected women. Calcif Tissue Int (2013) 0.80
Care of the human immunodeficiency virus-infected menopausal woman. Am J Obstet Gynecol (2011) 0.79
Prevalence and risk factors for osteopenia/osteoporosis in an HIV-infected male population. Wien Klin Wochenschr (2007) 0.78
Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection. Osteoporos Int (2014) 0.78
Radiographic evaluation of the chronological development of permanent dentition in children infected with HIV. Clin Oral Investig (2007) 0.78
Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIV. Osteoporos Int (2014) 0.78
Hormonal contraception and HIV-positive women: metabolic concerns and management strategies. J Midwifery Womens Health (2008) 0.78
HIV infection and osteoporosis. Bonekey Rep (2015) 0.77
DUAL-ENERGY X-RAY ABSORPTIOMETRY AND CALCULATED FRAX RISK SCORES MAY UNDERESTIMATE OSTEOPOROTIC FRACTURE RISK IN VITAMIN D-DEFICIENT VETERANS WITH HIV INFECTION. Endocr Pract (2015) 0.76
Increased risk of hip fracture associated with dually treated HIV/hepatitis B virus coinfection. J Viral Hepat (2015) 0.76
Elevated suppressor of cytokine signaling-1 (SOCS-1): a mechanism for dysregulated osteoclastogenesis in HIV transgenic rats. Pathog Dis (2014) 0.76
Fracture management in HIV positive individuals: a systematic review. Int Orthop (2016) 0.76
HIV associated hypocalcaemia among diarrheic patients in northwest Ethiopia: a cross sectional study. BMC Public Health (2014) 0.75
Prevalence of abnormal bone mineral density in hiv-positive patients in ibadan, Nigeria. J West Afr Coll Surg (2015) 0.75
Perspectives on menopause and women with HIV. Int J Womens Health (2016) 0.75
Low back pain and associated imaging findings among HIV-infected patients referred to an HIV/palliative care clinic. Pain Med (2013) 0.75
Bone effects of rosiglitazone in HIV-infected patients with lipoatrophy. HIV Clin Trials (2012) 0.75
Lifetime and recent alcohol use and bone mineral density in adults with HIV infection and substance dependence. Medicine (Baltimore) (2017) 0.75
Is PPARγ a prospective player in HIV-1-associated bone disease? PPAR Res (2009) 0.75
Bone health in HIV-infected children, adolescents and young adults: a systematic review. J AIDS Clin Res (2014) 0.75
Association of Blood Biomarkers of Bone Turnover in HIV-1 Infected Individuals Receiving Anti-Retroviral Therapy (ART). J AIDS Clin Res (2015) 0.75
Effect of Antiretroviral Therapy on Bone and Renal Health in Young Adults Infected with HIV in Early Life. J Clin Endocrinol Metab (2017) 0.75
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis (2010) 11.65
Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med (2008) 8.50
DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic Acids Res (2007) 6.89
Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2010) 6.00
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother (2003) 5.48
Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2012) 4.24
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med (2008) 3.71
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS (2009) 2.91
Bone disease and HIV infection. Clin Infect Dis (2005) 2.71
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr (2004) 2.55
Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin Infect Dis (2011) 2.54
Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis (2007) 2.34
Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis (2010) 2.20
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 2.17
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS (2005) 2.16
A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr (2005) 2.15
Bacterial community structures are unique and resilient in full-scale bioenergy systems. Proc Natl Acad Sci U S A (2011) 2.05
Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis (2011) 2.02
Nontuberculous pyogenic spinal infection in adults: a 12-year experience from a tertiary referral center. Spine (Phila Pa 1976) (2006) 2.00
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr (2002) 1.98
Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immune Defic Syndr (2007) 1.98
Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol Ther (2009) 1.97
Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis (2005) 1.95
Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS (2012) 1.90
The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. Arch Intern Med (2007) 1.84
Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS (2007) 1.78
HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS (2003) 1.66
Switching effective antiretroviral therapy: a review. Clin Infect Dis (2002) 1.66
Massively parallel pyrosequencing in HIV research. AIDS (2008) 1.63
Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J Infect Dis (2008) 1.63
Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis (2004) 1.57
Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138. J Infect Dis (2006) 1.57
A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis (2005) 1.56
Vitamin D deficiency is associated with type 2 diabetes mellitus in HIV infection. AIDS (2011) 1.55
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. J Antimicrob Chemother (2012) 1.54
Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384. Clin Infect Dis (2007) 1.47
The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest (2004) 1.45
Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis (2005) 1.43
Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis (2011) 1.40
Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med (2006) 1.40
Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med (2002) 1.36
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses (2012) 1.35
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS (2007) 1.29
Explaining, predicting, and treating HIV-associated CD4 cell loss: after 25 years still a puzzle. JAMA (2006) 1.27
Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr (2007) 1.27
The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswana. J Acquir Immune Defic Syndr (2008) 1.26
Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis (2013) 1.23
Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms. AIDS (2013) 1.23
Reducing plasma HIV RNA improves muscle amino acid metabolism. Am J Physiol Endocrinol Metab (2004) 1.22
Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. PLoS One (2008) 1.20
Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS (2011) 1.19
Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr (2007) 1.17
Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials (2010) 1.16
Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection. Hepatology (2012) 1.16
Human immunodeficiency virus type 1 Nef induces programmed death 1 expression through a p38 mitogen-activated protein kinase-dependent mechanism. J Virol (2008) 1.15
Whole-body proteolysis rate is elevated in HIV-associated insulin resistance. Diabetes (2006) 1.14
Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern Med (2013) 1.14
Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis. Clin Infect Dis (2013) 1.14
Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr (2005) 1.13
Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr (2006) 1.12
HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. AIDS Res Hum Retroviruses (2007) 1.11
Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis (2003) 1.10
Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips". Vaccine (2005) 1.09
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. J Acquir Immune Defic Syndr (2016) 1.07
A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102. J Acquir Immune Defic Syndr (2006) 1.06
Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men. AIDS (2009) 1.04
Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro. J Neuroimmune Pharmacol (2007) 1.03
Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis (2002) 1.03
Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. J Acquir Immune Defic Syndr (2012) 1.03
Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals. AIDS (2010) 1.02
Patterns of primary antiretroviral drug resistance in antiretroviral-naive HIV-1-infected individuals in a midwest university clinic. AIDS (2006) 1.02
Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin Infect Dis (2004) 1.02
The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications. Toxicol Pathol (2009) 1.01
Testosterone threshold levels and lean tissue mass targets needed to enhance skeletal muscle strength and function: the HORMA trial. J Gerontol A Biol Sci Med Sci (2010) 1.01
Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease. J Infect Dis (2005) 1.00
Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy. Metabolism (2005) 1.00
Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses (2004) 1.00
Visceral adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemia. Am J Physiol Endocrinol Metab (2003) 1.00
Cardiovascular risks of antiretroviral therapies. Annu Rev Med (2007) 1.00
HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts. AIDS Res Hum Retroviruses (2007) 0.99
N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone. J Clin Endocrinol Metab (2009) 0.97
Genetic analysis implicates resistin in HIV lipodystrophy. AIDS (2008) 0.96
Antiretroviral therapy after cryptococcal meningitis. N Engl J Med (2014) 0.96
Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial. Ann Intern Med (2015) 0.95
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). J Acquir Immune Defic Syndr (2007) 0.95
Risk factors for medication non-adherence in an HIV infected population in the Dominican Republic. AIDS Behav (2011) 0.94
European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS (2011) 0.93
Hepatitis C co-infection and severity of liver disease as risk factors for osteoporotic fractures among HIV-infected patients. J Bone Miner Res (2013) 0.92
Disease-modifying therapeutic concepts for HIV in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2011) 0.91